Summary
Synopsis: Budesonide1 is a non-halogenated glucocorticosteroid which has been shown to possess a high ratio of topical to systemic activity compared with a number of reference corticosteroids such as beclomethasone dipropionate, flunisolide, and triamcinolone acetonide. It appears to undergo extensive first-pass metabolism to metabolites of minimal activity which accounts for the low level of systemic activity.
The majority of therapeutic trials in asthma have been of short term duration and have demonstrated that conventional doses of inhaled budesonide (200 to 800 µg/day) and beclomethasone dipropionate (400 to 800 µg/day) are of similar efficacy in both adults and children with moderate to severe asthma. Other studies have compared high doses of inhaled budesonide (400 to 3200 µg/day in 4 divided doses) with both alternate day (7.5 to 60mg) and daily (7.5 to 40mg) oral prednisone in patients with severe or unstable asthma. In the small number of such trials to date, inhaled budesonide was superior to prednisone with respect to the level of asthma control and the lesser influence on adrenal function. Long term open studies have similarly shown that inhaled budesonide can be gradually substituted for oral prednisone in steroid-dependent patients, often with a concomitant improvement in pulmonary function and asthma control.
Intranasal budesonide (200 to 400 µg/day) relieves nasal symptoms in patients with seasonal allergic, perennial allergic and vasomotor rhinitis. In comparative studies in patients with seasonal rhinitis it has been shown to be of similar efficacy as intranasal flunisolide and intranasal beclomethasone dipropionate and superior to intranasal sodium cromoglycate (cromolyn sodium) and the antihistamine dexchlorpheniramine.
Following inhalation, the most commonly reported side effects have been candidiasis, dysphonia and sore throat, while after intranasal administration the most frequent adverse reactions have been nasal stinging, throat irritation, dry nose and slight nasal bleeding. At usual dosages, both formulations of budesonide appear to have little or no effect on adrenal function.
Thus, at this stage in its development budesonide has been shown to offer an effective alternative to oral or other inhaled corticosteroids in the management of asthma and rhinitis. However, its relative efficacy and tolerability during long term use, compared with beclomethasone dipropionate, remains to be clarified.
Pharmacodynamic Studies: In animals budesonide has a high ratio of topical to systemic activity compared with reference corticosteroids such as beclomethasone dipropionate, flunisolide and triamcinolone acetonide. In man, budesonide was shown to have 1.6 to 3 times greater local anti-inflammatory activity using a skin vasoconstriction assay, and between 2 and 4 times less systemic activity than beclomethasone dipropionate. The reduction in systemic potency in healthy volunteers should augur well for the clinical usefulness of budesonide, and trials in patients with asthma have not revealed any significant differences between conventional doses of budesonide and beclomethasone dipropionate. In practice, usual doses of inhaled or intranasal budesonide have caused only minimal changes in hypothalamic-pituitary-adrenal (HPA) function, although a doseresponse relationship with plasma cortisol concentrations has been documented. When inhaled therapy was substituted for oral prednisolone there was a gradual increase in plasma cortisol concentrations, highlighting the lower adrenal suppressive activity of budesonide compared with oral steroid.
Even after single doses, inhaled budesonide produced a rapid improvement in pulmonary function in patients with asthma, characterised by a dose-response relationship with peak expiratory flow rate. A divided daily regimen gave a more pronounced and longlasting increase in lung function at a reduced total daily dosage compared with a single daily dose.
The mechanism of action of budesonide, like that for other glucocorticoids, remains obscure. However, it has been noted that as long as pretreatment was sufficiently long, inhaled budesonide inhibited both the immediate and late reactions provoked by bronchial allergen challenge. Similarly, intranasal budesonide inhibited the type 1-mediated immediate nasal reaction and this may be related to suppression of histamine release in nasal biopsy samples in vitro.
Following intranasal administration of budesonide for up to 1 year in patients with rhinitis, no adverse morphological changes in the nasal mucosa occurred. However, no studies evaluating the histological characteristics of the bronchial mucosa after inhaled budesonide have been reported.
Pharmacokinetic Studies: In man, peak plasma concentrations of unchanged budesonide occurred within 1 hour of inhalation and approximately 3 hours after oral ingestion, thus reflecting the rapid rate of absorption from the lung. Systemic bioavailability was calculated to be 10.7% after oral administration, with evidence of extensive first-pass metabolism.
The volume of distribution of budesonide is comparatively large (301L), which is indicative of wide tissue distribution. Budesonide has been shown to be extensively bound to plasma proteins (88.3%) with negligible binding to transcortin. The relatively short elimination half-life (approximately 2 hours) and high plasma clearance (83.7 L/hour) highlight the rapid systemic elimination of budesonide. In vitro studies have corroborated the involvement of the liver in the rapid biotransformation of budesonide; 2 major metabolites with minimal activity have been isolated and identified. Only trace amounts of budesonide are excreted unchanged in the urine.
Therapeutic Trials: The majority of clinical trials with inhaled budesonide have been crossover studies designed to evaluate the effectiveness of different dosage regimens, or its comparative efficacy with that of inhaled beclomethasone dipropionate. Most were of short duration (2 to 4 weeks) and, when peak expiratory flow rate was measured, demonstrated a dose-response relationship over a wide range of inhaled dosages (100 to 1600 µg/day in divided doses) in patients with moderately severe and severe (steroiddependent) asthma. The dose-response relationship was maintained whether budesonide was administered twice or 4 times daily.
In short term comparative trials inhaled budesonide (400 to 3200 µg/day in 4 divided doses) was found to be superior to alternate-day oral prednisone (7.5 to 60mg) in patients with moderate to severe asthma, and was able to produce as effective control of unstable asthma as daily oral prednisone (7.5 to 40mg once daily). In this latter study, at doses producing equivalent control of the asthmatic condition, inhaled budesonide had significantly less effect on adrenal function. In other comparative trials, inhaled budesonide (200 to 800 µg/day) was of approximately equal efficacy as inhaled beclomethasone dipropionate (400 to 800 µg/day) in both adults and children with asthma. In long term open trials gradual substitution of inhaled budesonide for oral steroid has often resulted in an improvement in pulmonary function and asthma control. Oral steroid dosage was usually markedly decreased during budesonide administration, and 1600 µg/day of inhaled budesonide reduced mean oral prednisone usage by half.
Intranasal budesonide has been used in the treatment of seasonal allergic, perennial allergic and vasomotor rhinitis. In seasonal rhinitis doses of 200 to 400 µg/day were significantly better than placebo in relieving nasal symptoms and reducing the need for supplemental antiallergy medication, but had no effect on eye symptoms. In patients with seasonal allergic rhinitis, intranasal budesonide was as effective as intranasal beclomethasone dipropionate and intranasal flunisolide, and significantly superior to both intranasal sodium cromoglycate and the oral antihistamine dexchlorpheniramine. Short term comparisons in patients with perennial rhinitis, with or without an allergic component, have shown budesonide to be significantly better than placebo in relieving nasal symptoms when doses of 200 to 400 µg/day were administered. In long term open trials in patients with perennial rhinitis, intranasal budesonide (200 to 400 µg/day) has consistently produced a significant reduction in all nasal symptoms with a low incidence of mild and transient side effects.
In patients with nasal polyposis, budesonide was significantly more effective than placebo in reducing total symptom scores and increasing nasal peak flow rates, while rhinoscopy revealed a distinct decrease in nasal congestion, a decrease in polyp size, and a significant reduction in the number of polyps. However, only 10 patients received the active drug in this study and a well-designed trial in a greater number of patients is required to confirm the usefulness of intranasal budesonide in this condition.
Side Effects: Generally, budesonide has been well tolerated and few trials have reported adverse reactions associated with treatment. However, the majority of these studies have been of short term duration (2 to 4 weeks). Longer term trials in greater numbers of patients are required to fully evaluate the tolerability of budesonide.
Using the inhaled preparation, the most commonly reported side effects have been oropharyngeal candidiasis, hoarseness and sore throat, as is also the case with other inhaled corticosteroids. The reported incidence of candidiasis varied widely among studies, but was reduced by using a spacing device or by reverting to a less frequent dosing regimen. Gradual substitution of inhaled budesonide for oral prednisolone resulted in a number of side effects such as hoarseness, sore throat, arthralgia, myalgia, exacerbation of eczema and pulmonary eosinophilia and sarcoidosis, which can all be explained in terms of a local reaction or are indicative of systemic corticosteroid withdrawal. Administration of inhaled budesonide, up to 800 µg/day, appears to have a minimal effect on adrenal function as assessed by basal plasma cortisol concentrations and their increase after tetracosactrin stimulation. Nevertheless, during substitution of inhaled budesonide for oral corticosteroid, recovery of hypothalamic-pituitary-adrenal integrity can take up to 12 months after long term oral steroid therapy, and it is essential to take special care during this period.
Intranasal budesonide has been well tolerated, and in both long and short term trials in patients with rhinitis the most common side effects have been local reactions such as nasal stinging, throat irritation, dry nose and nasal bleeding. In comparative studies, intranasal budesonide has produced fewer adverse effects than the antihistamine dexchlorpheniramine, significantly less nasal irritation than flunisolide, and equivalent incidences of minor transient reactions as intranasal beclomethasone dipropionate and intranasal sodium cromoglycate. No evidence of adrenal suppression has been reported with this formulation.
Dosage and Administration: The inhaled dose of budesonide for the treatment of asthma in adults should be individualised. The recommended initial dose is 400 to 1600 µg/day divided into 2 or 4 administrations. The maintenance dose is usually 200 to 400 µg/day — using the lowest dose that leaves the patient symptom free. In children with asthma the recommended dose is 200 to 400 µg/day, divided into 2 or 4 administrations.
In the treatment of rhinitis the recommended dosage is 100µg (2 actuations of 50µg each) into each nostril morning and evening (400 µg/day). This dosage can be halved once a good response has been achieved.
Similar content being viewed by others
References
Ädelroth, E.; Rosenhall, L. and Glennow, C.: High dose inhaled budesonide in the treatment of severe steroid-dependent asthmatics — a two year study (In press, 1984).
Aherne, G.W.; Littleton, P.; Thalén, A. and Marks, V.: A sensitive radioimmunoassay for budesonide in plasma. Journal of Steroid Biochemistry 17: 559–565 (1982).
Andersson, P.: Effects of inhibitors of anaphylactic mediators in two models of bronchial anaphylaxis in anaesthetized guinea-pigs. British Journal of Pharmacology 77: 301–307 (1982).
Andersson, P. and Brattsand, R.: Protective effects of the glucocorticoid, budesonide, on lung anaphylaxis in actively sensitized guinea-pigs: Inhibition of IgE-but not of IgG-mediated anaphylaxis. British Journal of Pharmacology 76: 139–147 (1982).
Andersson, P.; Brattsand, R.; Brange, C.; Källström, L. and Stahre, G.: Effect of budesonide and beclomethasone dipropionate on antigen-induced bronchial anaphylaxis and plasma cortisol in guinea-pigs. Abstract submitted to the XII Congress of the European Academy of Allergology and Clinical Immunology. Rome (1983).
Andersson, P.: Brattsand, R.; Edsbäcker, S.; Källström, L. and Ryrfeldt, Å.: Biotransformation rate (in vitro) and systemic potency (in vivo) of the topical glucocorticoid budesonide in male and female rats. Journal of Steroid Biochemistry 17: 703–706 (1982a).
Andersson, P.; Chignard, M.; Le Couedic, J.-P.; Brange, C.; Nilsson, T. and Juhlin, M.: Effect of glucocorticosteroid (GCS) treatment on antigen-induced mediator release from sensitized guinea-pig lungs. Abstract submitted to the 3rd Congress of the European Society of Rheumatology (1984).
Andersson, P.; Edsbäcker, S.; Ryrfeldt, Å. and von Bahr, C.: In vitro biotransformation of glucocorticoids in liver and skin homogenate fraction from man. rat and hairless mouse. Journal of Steroid Biochemistry 16: 787–795 (1982b).
Balle, V.H.: The effect of budesonide in perennial rhinitis. European Journal of Respiratory Diseases 63 (Suppl. 122): 197–204 (1982).
Balle, V.H.; Pedersen, U. and Engby, B.: Allergic perennial and non-allergic, vasomotor rhinitis treated with budesonide nasal spray. Rhinology 18: 135–142 (1980).
Baran, D.: Budesonide in asthma (submitted for publication, 1984).
Bende, M.; Lindqvist, N. and Pipkorn, U.: Effect of a topical glucocorticoid, budesonide, on nasal mucosal blood flow as measured with 133Xe wash-out technique. Allergy 38: 461–464 (1983).
Bergstrand, H.; Björnsson, A.; Lundquist, B.; Nilsson, A. and Brattsand, R.: Inhibitory effect of glucocorticosteroids on anti-IgE-induced histamine release from human basophilic leukocytes: Evidence for a dual mechanism of action. Allergy 39: 217–230 (1984).
Bernstein, I.L.; Chervinsky, P. and Felliers, C.J.: Efficacy and safety of triamcinolone aerosol in chronic asthma. Chest 81: 20–26 (1982).
Björkander, J.; Formgren, H.; Johansson, S.Å. and Millqvist, E.: Methodological aspects on clinical trials with inhaled corticosteroids: Results of two comparisons between two steroid aerosols in patients with asthma. European Journal of Respiratory Diseases 63 (Suppl. 122): 108–117 (1982).
Brattsand, R. and Källström, L.: Importance of the skin barrier and of liver biotransformation on the systemic activity of topically applied budesonide. Acta Pharmaceutica Suecica 20: 36–37 (1983).
Brattsand, R.; Källström, L.; Nilsson, E.; Ryrfeldt, Å. and Tönnesson, M.: The lung disposition of budesonide in guinea pig and rat. European Journal of Respiratory Diseases 63 (Suppl. 122): 263–265 (1982a).
Brattsand, R.; Källström, L.; Wieslander, P.; Andersson, P.; Dahlbäck, M. and Dahl, R.: A model for particle-induced inflammation and edema formation in the rat lung and the antiinflammatory action of the glucocorticosteroid (GCS) budesonide in this model. Abstract submitted to the Edinburgh meeting of the European Society of Pneumology (1983).
Brattsand, R.; Thalén, A.; Roempke, K.; Källström, L. and Gruvstad, E.: New glucocorticoids with improved ratio between topical and systemic activities. British Journal of Pharmacology 77: 433P (1982b).
Brattsand, R.; Thalén, A.; Roempke, K.; Källström, L. and Gruvstad, E.: Influence of 16α, 17α-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. Journal of Steroid Biochemistry 16: 779–786 (1982c)
Brattsand, R.; Thalén, A.; Roempke, K.; Källström, L. and Gruvstad, E.: Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. European Journal of Respiratory Diseases 63 (Suppl. 122): 62–73 (1982d).
Breslin, A.B.X.; Pepys, J.; Davies, R.J. and Hendrick, D.J.: Effect of beclomethasone dipropionate on antigen bronchial challenge in asthmatic patients. Australian and New Zealand Journal of Medicine 3: 324 (1973).
British Thoracic and Tuberculosis Association: Inhaled corticosteroids compared with oral prednisone in patients starting long term corticosteroid therapy for asthma. Lancet 2: 469–473 (1975).
Brogden, R.N.: Inhaled steroids: Pharmacology and toxicology; in Clark (Ed.) Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy, pp. 121–134 (ADIS Press, Auckland 1983a).
Brogden, R.N.: Inhaled steroids: Studies in adult and childhood asthma; in Clark (Ed.) Steroids in Asthma: A Reappraisal in Light of Inhalation Therapy, pp. 135–153 (ADIS Press, Auckland 1983b).
Brogden, R.N.: Factors which may affect the response to inhaled steroids; side effects; in Clark (Ed.) Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy, pp. 154–165 (ADIS Press, Auckland 1983c).
Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Beclomethasone dipropionate: A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs 28: 99–126 (1984).
Burge, P.S.: The effects of corticosteroids on the immediate asthmatic reaction. European Journal of Respiratory Diseases 63 (Suppl. 122): 163–166 (1982).
Cameron, A.W.; Stanley, I.M. and Wright, H.J.: Randomised double blind controlled clinical trial of intranasal budesonide in treatment of hay fever. British Medical Journal 288: 1881–1884 (1984).
Chiang, J.L.; Patterson, R.; McGillen, J.J.; Phair, J.P.; Roberts, M.; Harris, K.E. and Riesing, K.S.: Long term corticosteroid effect on lymphocyte and polymorphonuclear cell function in asthmatics. Journal of Allergy and Clinical Immunology 65: 263–268 (1980).
Cochrane, G.M.: Systemic steroids in asthma; in Clark (Ed.) Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy, pp. 103–120 (ADIS Press, Auckland 1983).
Dahl, R. and Johansson, S.-Å.: Clinical effect of bid and qid administration of inhaled budesonide. A double-blind controlled study. European Journal of Respiratory Diseases 63 (Suppl. 122): 268–269 (1982a).
Dahl, R. and Johansson, S.-Å.: Effect of inhaled budesonide on dual asthmatic reactions. Allergy 37 (Suppl. 1): 19 (1982b).
Dahl, R. and Johansson, S.-Å.: Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. European Journal of Respiratory Diseases 63 (Suppl. 122): 167–175 (1982c).
Dahl, R. and Johansson, S.-Å.: Effect on lung function of budesonide by inhalation, terbutaline s.c. and placebo given simultaneously or as single treatments. European Journal of Respiratory Diseases 63 (Suppl. 122): 132–137 (1982d).
Dahlberg, E.; Thalén, A.; Brattsand, R.; Gustafsson, J.A.; Johansson, U.; Roempke, K. and Saartok, T.: Correlation between chemical structure, receptor binding and biological activity of some novel, high active, 16α, 17α-acetal-substituted glucocorticoids. Molecular Pharmacology 25: 70–78 (1984).
Ebden, P. and Davies, B.H.: High-dose corticosteroid inhalers for asthma. Lancet 2: 576 (1984).
Edsbäcker, S.; Jönsson, S.; Lindberg, C.; Ryrfeldt, Å. and Thalén, A.: Metabolic pathways of the topical glucocorticoid budesonide in man. Drug Metabolism and Disposition 11: 590–596 (1983).
Ellul-Micallef, R.; Hansson, E. and Johansson, S.-Å.: Budesonide: A new corticosteroid in bronchial asthma. European Journal of Respiratory Diseases 61: 167–173 (1980).
Ellul-Micallef, R. and Johansson, S.-Å.: Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide. British Journal of Clinical Pharmacology 15: 419–422 (1983a).
Ellul-Micallef, R. and Johansson, S.-Å.: Dose-frequency in chronic bronchial asthma with a new corticosteroid budesonide; in Johansson, S.Å. (Ed.) Evaluation of Budesonide — a new glucocorticosteroid for local treatment of asthma (University of Lund, 1983b).
Field, H.V.; Jenkinson, P.M.A.; Frame, M.H. and Warner, J.O.: Asthma treatment with a new corticosteroid aerosol, budesonide, administered twice daily by spacer inhaler. Archives of Disease in Childhood 57: 864–866 (1982).
Forsberg, K.; Ryrfeldt, Å. and Sörenby, L.: Protective effects of budesonide on lung anaphylaxis in actively sensitized guinea pigs: Inhibition of ‘IgG’-mediated anaphylaxis. European Journal of Respiratory Diseases 63 (Suppl. 122): 257–259 (1982).
Forsberg, K. and Sörenby, L.: The influence of a new corticosteroid, budesonide, on anaphylactic bronchoconstriction and SRS-A release in the guinea pig. Agents and Actions 11: 391–395 (1981).
Gruvstad, E. and Bengtsson, B.: A comparison of a new steroid, budesonide, with other topical corticosteroids in the vasoconstriction assay. Drugs Under Experimental and Clinical Research 6: 385–390 (1980).
Hartley, J.P.R.; Charles, T.J. and Seaton, A.: Betamethasone valerate inhalation and exercise-induced asthma in adults. British Journal of Diseases of the Chest 71: 253–258 (1977).
Henriksen, J.M.: Effects of budesonide inhalation therapy on exercise-induced asthma in children (Submitted for publication, 1984).
Henriksen, J.M. and Dahl, R.: Effects of inhaled budesonide alone and in combination with low-dose terbutaline in children with exercise-induced asthma. American Review of Respiratory Disease 128: 993–997 (1983).
Henriksen, J.M. and Wenzel, A.: Effect of intranasal corticosteroid (Budesonide) on children with asthma and perennial rhinitis. Folia Allergologica et Immunologica Clinica 30 (Suppl. 4): 29 (1983).
Hodgson, S.V.; McPherson, A. and Friedman, M.: The effect of betamethasone valerate aerosol on exercise-induced asthma in children. Postgraduate Medical Journal 50 (Suppl. 4): 69–72 (1974).
Holopainen, E.; Grahne, B.; Malmberg, H.; Mäkinen, J. and Lindqvist, N.: Budesonide in the treatment of nasal polyposis. European Journal of Respiratory Diseases 63 (Suppl. 122): 221–228 (1982).
Johansson, S.-Å.; Andersson, K.-E.; Brattsand, R.; Gruvstad, E. and Hedner, P.: Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. European Academy of Allergology and Clinical Immunology 2: 709–715 (1982a).
Johansson, S.-Å.; Andersson, K.-E.; Brattsand, R.; Gruvstad, E. and Hedner, P.: Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. European Journal of Respiratory Diseases 63 (Suppl. 122): 74–82 (1982b).
Johansson, S.-Å.; Andersson, K.-E.; Brattsand, R.; Gruvstad, E. and Hedner, P.: Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. European Journal of Clinical Pharmacology 22: 523–529 (1982c).
Johansson, S.-Å. and Dahl, R.: A double-blind dose response study of budesonide by inhalation in patients with bronchial asthma (submitted for publication, 1984).
Kay, A.B.: The immunological basis of asthma; in Clark (Ed.) Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy. pp. 46–60 (ADIS Press, Auckland 1983).
Kjellman, M.; Möller, C.; Glennow, C. and Konar, A.: A comparison of Becotide® and budesonide in children. European Journal of Respiratory Diseases 63 (Suppl. 124): 127 (1982).
Laursen, L.C.; Taudorf, E.; Weeke, B. and Glennow, C.: High-dose inhaled budesonide in treatment of severe steroid-dependent asthmatics. Lancet 2: 1305 (1983).
Lewis, L.D. and Cochrane, G.M.: Psychosis in a child inhaling budesonide. Lancet 2: 634 (1983).
Lindqvist, N.; Balle, V.; Karma, P.; Kärjä, J.; Lindström, D.; Mäkinen, J.; Pipkorn, U.; Pukander, J.; Suonpää, J. and Östlund, W.: A 12-month open tolerance study with budesonide nasal aerosol in perennial rhinitis. A multicentre study. Fifth Asia-Oceania Congress of Otorhinolaryngological Societies (Korea), p. 335 (1983).
Lindqvist, N.; Balle, V.; Karma, P.; Lindström, D.; Pipkorn, U.; Suonpää, J. and Östlund, W.: Six-month open tolerance study with budesonide nasal aerosol in patients suffering from perennial rhinitis: A multicentre trial. European Journal of Respiratory Diseases 63 (Suppl. 122): 270–271 (1982).
Löfdahl, C.-G.; Mellstrand, T. and Svedmyr, N.: Glucocorticoids and asthma. Studies of resistance and systemic effects of glucocorticoids. European Journal of Respiratory Diseases 65 (Suppl. 136): 69–79 (1984).
Malm, L.; Wihl, J.Å.; Lamm, C.J. and Lindqvist, N.: Reduction of metacholine-induced nasal secretion by treatment with a new topical steroid in perennial non-allergic rhinitis. Allergy 36: 209–214 (1981).
McGivern, D.V. and Macfarlane, J.: Severe bronchoconstrictionafter inhalation of budesonide. British Medical Journal 288: 447 (1984).
Morén, F. and Andersson, J.: Fraction of dose exhaled after administration of pressurized inhalation aerosols. International Journal of Pharmaceutics 6: 295–300 (1980).
Munch, E.P.; Søborg, M.; Nørreslet, T.T. and Mygind, N.: A comparative study of dexchlorpheniramine maleate sustained release tablets and budesonide nasal spray in seasonal allergic rhinitis. Allergy 38: 517–524 (1983).
Munch, E.P.; Weeke, B. and Johansson, S.-Å.: The effect of budesonide on nasal allergen challenge in patients with seasonal rhinitis and on nasal peak flow in healthy volunteers. European Journal of Respiratory Diseases 63 (Suppl. 122): 176–184 (1982).
Newman, S.P.: The correct use of inhalers; in Clark (Ed.) Steroids in Asthma: A reappraisal in the Light of Inhalation Therapy, pp. 210–226 (ADIS Press, Auckland 1983).
Newman, S.P.: Móren. F.; Pavia, D.; Little, F. and Clarke, S.W.: Deposition of pressurized suspension aerosols inhaled through extension devices. American Review of Respiratory Diseases 124: 317–320 (1981).
Norman, P.S.; Tobey, R.E. and Creticos, P.S.: Nasal corticosteroid (Budesonide) lowers TAME-esterase levels in nasal washes while controlling hay fever symptoms. Journal of Allergy and Clinical Immunology 73 (Suppl.): 142 (1984).
Nyholm, E.; Frame, M.H. and Cayton, R.M.: Therapeutic advantages of twice-daily over four-times daily administration of the corticosteroid aerosol budesonide in chronic asthma. European Journal of Respiratory Diseases (In press, 1984).
Pelikan, Z. and Pelikan-Filipek, M.: The effects of disodium cromoglycate and beclomethasone dipropionate on the immediate response of the nasal mucosa to allergen challenge. Annals of Allergy 49: 283–292 (1982).
Pepys, J.; Davies, R.J.; Breslin, A.B.X.; Hendrick, D.J. and Hutchcroft, B.J.: The effect of inhaled beclomethasone dipropionate (Becotide) and sodium cromoglycate on asthmatic reactions to provocation tests. Clinical Allergy 4: 13–24 (1974).
Pipkorn, U.: Budesonide and nasal allergen challenge testing in man. Allergy 37: 129–134 (1982a).
Pipkorn, U.: Budesonide and nasal histamine challenge. Allergy 37: 359–363 (1982b).
Pipkorn, U.: The effect of budesonide on the immediate reaction to allergen challenge — a rhinomanometric study. European Journal of Respiratory Diseases 63 (Suppl. 122): 185–191 (1982c).
Pipkorn, U.: Effect of topical glucocorticoid treatment on nasal mucosal mast cells in allergic rhinitis. Allergy 38: 125–129 (1983a).
Pipkorn, U.: Hay fever treatment with budesonide and beclomethasone dipropionate twice daily — a clinical comparison. Rhinology 21: 335–340 (1983b).
Pipkorn, U. and Andersson, P.: Budesonide and nasal mucosal histamine content and anti-IgE induced histamine release. Allergy 37: 591–595 (1982).
Pipkorn, U. and Berge, T.: Long-term treatment with budesonide in vasomotor rhinitis. Acta Oto-Laryngologica 95: 167–171 (1983).
Pipkorn, U. and Geterud, Å.: A comparative trial testing budesonide and flunisolide nasal sprays in patients with seasonal allergic rhinitis. Annals of Allergy 52: 183–186 (1984).
Pipkorn, U. and Rundcrantz, H.: Budesonide and beclomethasone dipropionate in hay fever — a single blind comparison. European Journal of Respiratory Diseases 63 (Suppl. 122): 211–220 (1982).
Pipkorn, U.; Rundcrantz, H. and Lindqvist, N.: Budesonide — a new nasal steroid. Rhinology 18: 171–175 (1980).
Rosenhall, L.; Ädelroth, E. and Johansson, S.-Å.: One year treatment with high doses of a new steroid aerosol (budesonide) in steroid dependent asthmatic patients. European Academy of Allergology and Clinical Immunology 2: 777–783 (1982a).
Rosenhall, L.; Lundqvist, G.; Ädelroth, E. and Glennow, C.: Comparison between inhaled and oral corticosteroids in patients with chronic asthma. European Journal of Respiratory Diseases 63 (Suppl. 122): 154–162 (1982b).
Roth, G.; Wikby, A.; Nilsson, L. and Thalén, A.: High-performance liquid Chromatographic determination of epimers, impurities and content of the glucocorticoid budesonide and preparation of primary standard. Journal of Pharmaceutical Sciences 69: 766–770 (1980).
Ryrfeldt, Å.; Andersson, P.; Edsbäcker, S.; Tönnesson, M.; Davies, D. and Pauwels, R.: Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. European Journal of Respiratory Diseases 63 (Suppl. 122): 86–95 (1982).
Ryrfeldt, Å.; Edsbäcker, S. and Pauwels, R.: Kinetics of the epimeric glucocorticoid budesonide. Clinical Pharmacology and Therapeutics 35: 525–530 (1984).
Ryrfeldt, Å.; Tönnesson, M.; Nilsson, E. and Wikby, A.: Pharmacokinetic studies of a potent glucocorticoid (budesonide) in dogs by high-performance liquid chromatography. Journal of Steroid Biochemistry 10: 317–324 (1979).
Saavedra-Delgado, A.M.P.; Mathews, K.P.; Pan, P.M.; Kay, D.R. and Muilenberg, M.L.: Dose-response studies of the suppression of whole blood histamine and basophil counts by prednisone. Journal of Allergy and Clinical Immunology 66: 464–471 (1980).
Samuelsson, A.: A comparison between budesonide and beclomethasone-dipropionate in patients with birch-pollen induced hay fever. Folia Allergologica et Immunologica Clinica 30 (Suppl. 4): 102 (1983).
Spangler, D.L.; Bloom, F.L.; Brestel, E.P. and Wittig, H.J.: One year trial of aerolized flunisolide in severe steroid-dependent asthmatics. (Abstract No. 186.) Annals of Allergy 39: 70 (1979).
Steensen, H. and Lindqvist, N.: Treatment of grass pollen-induced hay fever with intranasal budesonide. Allergy 36: 245–249 (1981).
Stiksa, G.; Glennow, C. and Johannesson, N.: An open cross-over trial with budesonide and beclomethasone dipropionate in patients with bronchial asthma. European Journal of Respiratory Diseases 63 (Suppl. 122): 266–267 (1982).
Svensjö, E. and Roempke, K.: Time dependent inhibition of bradykinin induced microvascular permeability increase by local glucocorticoid treatment. Abstract submitted to the 3rd Congress of the European Society of Rheumatology (1984).
Thalén, A. and Brattsand, R.: Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity. Arzneimittel-Forschung 29: 1687–1690 (1979).
Thalén, A.; Brattsand, R. and Gruvstad, E.: Synthesis and pharmacological properties of some 16α, 17α acetals of 16α-hydroxyhydrocortisone, 16α-hydroxyprednisolone and fluorinated 16α-hydroxyprednisolones. Acta Pharmaceutica Suecica 21: 109–124 (1984).
Tivenius, L.; Kiviloog, J. and Glennow, C.: The effect of budesonide on bronchial provocation after varying lengths of pretreatment. European Journal of Respiratory Diseases 63 (Suppl. 122): 126 (1982).
Toogood, J.H.: Steroids in asthma. Lancet 2: 1185 (1979).
Toogood, J.H.: Concentrated aerosol formulations in asthma. Lancet 2: 790–791 (1983).
Toogood, J.; Baskerville, J.; Jennings, B. and Johansson, S.-Å.: Inhaled budesonide (B) vs. daily oral prednisone (P) for preventing asthma relapses in unstable asthmatics. Abstract submitted to the Scientific Program, American College of Chest Physicians and International Academy of Chest Physicians and Surgeons. Portugal (1984d).
Toogood, J.; Baskerville, J.C.; Jennings, B.; Johansson, S.-Å. and Lefcoe, N.: Influence of dose-frequency and periodicity on response to aerosol steroids (AS) in asthma. Journal of Allergy and Clinical Immunology 69: 130 (1982a).
Toogood, J.H.; Baskerville, J.C.; Jennings, B.; Lefcoe, N.M. and Johansson, S.-Å.: Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. Journal of Allergy and Clinical Immunology 70: 288–298 (1982b).
Toogood, J.H.; Baskerville, J.; Jennings, B.; Lefcoe, N.M. and Johansson, S.-Å.: Use of spacers to facilitate inhaled corticosteroid treatment of asthma. American Review of Respiratory Diseases 129: 723–729 (1984c).
Toogood, J.H.; Jennings, B.; Baskerville, J.; Anderson, J. and Johansson, S.-Å.: Dosing regimen of budesonide and occurrence of oropharyngeal complications. European Journal of Respiratory Diseases 65: 35–44 (1984a).
Toogood, J.H.; Jennings, B.; Baskerville, J. and Johansson, S.-Å.: Clinical use of spacer systems for corticosteroid inhalation therapy: A preliminary analysis. European Journal of Respiratory Diseases 63 (Suppl. 122): 100–107 (1982c).
Toogood, J.H.; Jennings, B.; Baskerville, J. and Johansson, S.-Å.: Which asthmatic patients respond best to a spacer (Sp)? Journal of Allergy and Clinical Immunology 73 (Suppl.): 121 (1984b).
Toogood, J.H.; Jennings, B.; Baskerville, J.; Lefcoe, N. and Johansson, S.-Å.: Comparison of alternate-morning prednisone vs. inhaled steroid (IS) for asthma. Annals of the Royal College of Physicians and Surgeons of Canada 16: 308 (1983).
Toogood, J.H.; Jennings, B.; Baskerville, J.; Lefcoe, N. and New-house, M.: Assessment of a device for reducing oropharyngeal complications during beclomethasone treatment of asthma. American Review of Respiratory Diseases 123: 113 (1981).
Vilsvik, J.S.; Jensen, A.O. and Wahlstad, R.: The effect of beclomethasone dipropionate aerosol on allergen-induced nasal stenosis. Clinical Allergy 5: 291–294 (1975).
Warland, A.; Moller, P. and Lindqvist, N.: Budesonide — a new steroid for intranasal use. A double-blind clinical comparison between budesonide and placebo in patients with seasonal allergic rhinitis. Allergy 36: 425–428 (1981).
Webb, J.: Some tests of pituitary adrenal function and their application to the management of steroid-treated asthmatic patients; in Clark (Ed.) Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy, pp. 227–233 (ADIS Press, Auckland 1983).
Wenzel, A.; Henriksen, J. and Meisen, B.: Nasal respiratory resistance and head posture: Effect of intranasal corticosteroid (Budesonide) in children with asthma and perennial rhinitis. American Journal of Orthodontics 84: 422–426 (1983).
Wikby, A.; Thalén, A. and Oresten, G.: Separation of epimers of budesonide and related corticosteroids by high-performance liquid chromatography: A comparison between straight- and reversed-phase systems. Journal of Chromatography 157: 65–74 (1978).
Willey, R.F.; Godden, D.J.; Carmichael, J.; Preston, P.; Frame, M. and Crompton, G.K.: Comparison of twice daily administration of new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma. British Journal of Diseases of the Chest 76: 61–68 (1982).
Wyatt, R.; Waschek, J.; Weinberger, M. and Sherman, B.: Effects of inhaled beclomethasone dipropionate and alternate-day prednisone on pituitary-adrenal function in children with chronic asthma. New England Journal of Medicine 299: 1387 (1978).
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: G.M. Cochrane, Department of Thoracic Medicine, Guy’s and New Cross Hospitals, London, England; R. Dahl, Department of Pulmonary Diseases, Å;rhus Kommunehospital, Århus, Denmark; J.M. Henriksen, Department of Paediatrics, Århus University Hospital, Århus, Denmark; R.T. Jackson Laboratory of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USA; A.B. Kay, Department of Allergy and Clinical Immunology, The Cardiothoracic Institute, London, England; J. Morrison-Smith, Penyraber, Fishguard, Wales; N. Mygind, University ENT Department, Rigshospitalet, Copenhagen, Denmark; J.J Rohwedder, Pulmonary Disease Section, Veterans Administration Medical Center, Phoenix, Arizona, USA; J.H. Toogood, Allergy Clinic, Victoria Hospital, London, Ontario, Canada; J.O. Warner, Brompton Hospital, London, England; M.H. Williams, Pulmonary Division, Department of Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx Municipal Hospital Center, New York, USA; J.D. Wilson, Department of Immunobiology, School of Medicine, University of Auckland, New Zealand.
‘Pulmicort’,‘Rhinocort’ ‘Spirocort’ (Astra).
Rights and permissions
About this article
Cite this article
Clissold, S.P., Heel, R.C. Budesonide. Drugs 28, 485–518 (1984). https://doi.org/10.2165/00003495-198428060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198428060-00001